Abstract 1942P
Background
B-MPT accounts for <1% of breast neoplasms. The standard treatment for non-metastatic disease consists of wide local excision. Type of excision and adjuvant treatments are still matter of debate. Because of its rarity, only few case series with less than 100 B-MPT patients (pts) are available.
Methods
We conducted a retrospective single-centre observational study to describe outcomes and possible prognostic factors of pts with B-MPT. Data of consecutive patients aged ³18 years old, with a histologically confirmed diagnosis of non-metastatic B-MPT, who underwent surgery from January 2000 to December 2021, were collected. The primary endpoint was recurrence-free survival (RFS). Survival was calculated using Kaplan–Meier method. Multivariable analysis was performed with Cox proportional hazards model (significance at p-value<0.05).
Results
131 pts were included. Patient characteristics are reported in table. All patients received a surgery, 5 adjuvant anthracycline-based chemotherapy and 15 radiation therapy. After a median follow-up of 6.8 years, 36 (28%) pts experienced a disease recurrence: 19 (15%) a distant and 23 (18%) a loco-regional relapse. The median RFS, distant RFS (DRFS) and local RFS (LRFS) were not reached. The 5-year RFS, DRFS and LRFS rates were of 72%, 85% and 82%. At univariate analysis DRFS significantly correlated with the presence of at least one negative pathological prognostic factor (i.e., Size >5 cm, Multifocal disease or Heterologous differentiation [SMH]) (p=.03). If adjusted for type of breast surgery, SMH was associated also with LRFS (HR 3.3; 95%CI, 1.4-7.8; p=.008). The type of surgery was not prognostic for RFS, DRFS and LRFS.
Table: 1942P
Patient characteristics
N=131 | |
Age at diagnosis, mean (DS) | 46.7 (12.7) |
Negative pathological prognostic factors | |
Size >5 cm - % | 43% |
Multifocal disease - % | 11% |
Heterologous differentiation - % | 20% |
At least one negative prognostic factor - % | 62% |
Surgery strategy | |
Upfront wide local excision with attention to margins - % | 45% |
Re-excision after previous inadequate resection - % | 46% |
Inadequate resection without re-excision - % | 9% |
Type of last breast surgery | |
Excisional biopsy (no attempt at margins) - % | 9% |
Lumpectomy (wide local excision with attention to margins) - % | 34% |
Mastectomy - % | 57% |
pR1 - % | 14% |
Adjuvant chemotherapy - % | 4% |
Adjuvant radiotherapy - % | 11% |
Conclusions
Natural history of B-MPT is burdened by local and distant recurrences. Pathological features more than the type of wide local excision seem to represent the most significant prognostic factor for recurrences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Pfizer; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Personal, Other, Advisory Board: Ellipsis; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Invited Speaker, phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Member of Board of Directors, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Advisory Role, Member of the Scientific Council. Patient advocacy association: Europa Donna; Non-Financial Interests, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Officer, Member of the Advisory Council: EUSOMA; Non-Financial Interests, Officer, ESMO Clinical Practice Guidelines Chair: ESMO. All other authors have declared no conflicts of interest.
Resources from the same session
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15